These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1354678)

  • 1. Generation and characterization of IL-2-activated veto cells.
    Fast LD
    J Immunol; 1992 Sep; 149(5):1510-5. PubMed ID: 1354678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease.
    Via CS; Sharrow SO; Shearer GM
    J Immunol; 1987 Sep; 139(6):1840-9. PubMed ID: 2957440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro characterization of a murine recipient anti-donor effector cell responsible for the development of chronic graft-versus-host disease.
    Fast LD
    J Immunol; 1991 Sep; 147(6):1731-8. PubMed ID: 1909729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporine A and peripheral tolerance. Inhibition of veto cell-mediated clonal deletion of postthymic precursor cytotoxic T lymphocytes.
    Hiruma K; Gress RE
    J Immunol; 1992 Sep; 149(5):1539-47. PubMed ID: 1387142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DBA/2J and DBA/2Ha lymphocytes differ in their ability to induce graft-vs-host disease.
    Fast LD
    J Immunol; 1989 Oct; 143(8):2489-93. PubMed ID: 2794505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency analysis of lymphokine-secreting CD4+ and CD8+ T cells activated in a graft-versus-host reaction.
    Kelso A
    J Immunol; 1990 Oct; 145(7):2167-76. PubMed ID: 1975827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-10: a novel cytotoxic T cell differentiation factor.
    Chen WF; Zlotnik A
    J Immunol; 1991 Jul; 147(2):528-34. PubMed ID: 1906502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the mechanisms of T cell-dependent polyclonal activation of human B cells. Induction of human B cell responses by fixed activated T cells.
    Tohma S; Lipsky PE
    J Immunol; 1991 Apr; 146(8):2544-52. PubMed ID: 1707911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H; Chang AE; Shu SY
    Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease.
    Via CS; Rus V; Gately MK; Finkelman FD
    J Immunol; 1994 Nov; 153(9):4040-7. PubMed ID: 7930611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cloned cytolytic T cells can suppress primary cytotoxic responses directed against them.
    Fink PJ; Rammensee HG; Bevan MJ
    J Immunol; 1984 Oct; 133(4):1775-81. PubMed ID: 6332132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGF-beta mediates natural suppressor activity of IL-2-activated lymphocytes.
    Yamamoto H; Hirayama M; Genyea C; Kaplan J
    J Immunol; 1994 Apr; 152(8):3842-7. PubMed ID: 8144953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic and functional analysis of murine CD3+,CD4-,CD8- TCR-gamma delta-expressing peripheral T cells.
    Cron RQ; Gajewski TF; Sharrow SO; Fitch FW; Matis LA; Bluestone JA
    J Immunol; 1989 Jun; 142(11):3754-62. PubMed ID: 2523934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
    Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
    J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human resting B lymphocytes can serve as accessory cells for anti-CD2-induced T cell activation.
    Hirokawa M; Gray JD; Takahashi T; Horwitz DA
    J Immunol; 1992 Sep; 149(6):1859-66. PubMed ID: 1355500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mlsa generated suppressor cells. I. Suppression is mediated by double-negative (CD3+CD5+CD4-CD8-) alpha/beta T cell receptor-bearing cells.
    Bruley-Rosset M; Miconnet I; Canon C; Halle-Pannenko O
    J Immunol; 1990 Dec; 145(12):4046-52. PubMed ID: 1701781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppressor T cells, distinct from "veto cells," are induced by alloantigen priming and mediate transferable suppression of cytotoxic T lymphocyte responses in vivo.
    Owens T; Crispe IN
    J Immunol; 1985 Nov; 135(5):2984-9. PubMed ID: 2413108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
    Anderson PM; Blazar BR; Bach FH; Ochoa AC
    J Immunol; 1989 Feb; 142(4):1383-94. PubMed ID: 2521662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.